Blair William & Co. IL Cuts Stock Position in The Cooper Companies, Inc. $COO

Blair William & Co. IL decreased its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 38.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,745 shares of the medical device company’s stock after selling 13,314 shares during the quarter. Blair William & Co. IL’s holdings in Cooper Companies were worth $1,547,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of COO. Exchange Traded Concepts LLC raised its position in Cooper Companies by 16.3% in the first quarter. Exchange Traded Concepts LLC now owns 1,502 shares of the medical device company’s stock worth $127,000 after acquiring an additional 210 shares in the last quarter. Prentiss Smith & Co. Inc. purchased a new position in Cooper Companies in the first quarter worth $4,150,000. State of Alaska Department of Revenue raised its position in Cooper Companies by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 23,390 shares of the medical device company’s stock worth $1,972,000 after acquiring an additional 680 shares in the last quarter. Boston Trust Walden Corp raised its position in Cooper Companies by 4.3% in the first quarter. Boston Trust Walden Corp now owns 1,437,977 shares of the medical device company’s stock worth $121,293,000 after acquiring an additional 58,687 shares in the last quarter. Finally, Covea Finance raised its position in Cooper Companies by 95.7% in the first quarter. Covea Finance now owns 46,000 shares of the medical device company’s stock worth $3,880,000 after acquiring an additional 22,500 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Down 3.4%

COO opened at $68.76 on Thursday. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29. The firm has a market cap of $13.67 billion, a P/E ratio of 33.87, a PEG ratio of 1.87 and a beta of 1.02. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $109.04. The business’s fifty day simple moving average is $69.43 and its 200 day simple moving average is $73.43.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has initiated a share repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Cooper Companies

In other Cooper Companies news, COO Daniel G. Mcbride purchased 3,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were purchased at an average cost of $65.04 per share, with a total value of $195,120.00. Following the purchase, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. This represents a 4.99% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Brian G. Andrews purchased 1,525 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was acquired at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the completion of the purchase, the executive vice president owned 22,191 shares in the company, valued at $1,457,504.88. The trade was a 7.38% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 17,975 shares of company stock worth $1,216,346 in the last quarter. 1.98% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Cooper Companies in a research report on Wednesday, October 8th. Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the stock an “equal weight” rating in a research report on Thursday, August 28th. Wells Fargo & Company dropped their price target on Cooper Companies from $93.00 to $72.00 and set an “overweight” rating for the company in a research report on Thursday, August 28th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target for the company in a research report on Tuesday, July 22nd. Finally, Wall Street Zen cut Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cooper Companies presently has an average rating of “Moderate Buy” and a consensus target price of $84.77.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.